实验动物与比较医学2018，Vol.38Issue(2)：105-110,6.DOI:10.3969/j.issn.1674-5817.2018.02.005
壬二酸佐剂对甲型肝炎减毒活疫苗诱导小鼠体液免疫应答效应分析
Effects of Azelaic Acid Adjuvant on Humoral Immune Response Induced by Hepatitis A Virus Attenuated Live Vaccine in Mice
摘要
Abstract
Objective To investigate the effect of azelaic acid as an adjuvant on humoral immune response induced by hepatitis A virus (HAV) attenuated live vaccine (HepA-1) in mice to evaluate its adjuvant effect.Methods The ICR mice were injected respectively with HepA-1(18EU) and Al(OH)3 (300 rag) and four different doses(0.5 mg,1 mg,2 mg,3 mg) of azelaic acid as adjuvant group,300 μL for each and one immunization.At the same time,set up the blank group,pure vaccine group,aluminum adjuvant control group.The sera from tail vein blood of mice were collected at the end of 4,8,12 and 16 weeks after immunization and the specific IgG antibody against HAV were detected by indirect ELISA method.Results In addition to the blank group,mice in various groups generated Anti-HAV IgG at 4,8,12,16 weeks after the immunization.The antibody levels increased as time went on and reached peak at the 8th and 12th week,then decreased gradually.At 4 weeks,the level of anti-hepatitis A virus (HAV) IgG produced by adjuvant group 4 (azelaic acid 3 mg) was significantly higher than aluminum adjuvant control group (P＜0.05,t =2.640).At the same time,the level of anti-hepatitis A virus (HAV) IgG in adjuvant group 4 was significantly higher at 4th week,8th week and 12th week than pure antigen group (P＜0.05,t =3.134,2.751,2.743).Conclusion Appropriate dose of azelaic acid can obviously enhance the HepA-1 induced humoral immune response in mice.Azelaic acid is expected to become a new adjuvant for human vaccines.关键词
壬二酸/疫苗佐剂/甲型肝炎减毒活疫苗(HepA-1)/体液免疫Key words
Azelaic acid/Vaccine adjuvant/Hepatitis A virus attenuated live vaccine(HepA-1)/Humoral immunity分类
生物科学引用本文复制引用
李晓红,金晓,贾森泉,胡凝珠,胡云章,李建芳..壬二酸佐剂对甲型肝炎减毒活疫苗诱导小鼠体液免疫应答效应分析[J].实验动物与比较医学,2018,38(2):105-110,6.基金项目
国家重点研发计划“高等级病原微生物实验室模拟培训体系研究”(2016YFC1202305) （2016YFC1202305）
国家自然科学基金(31500724 （）
31500748) （）
云南省重大科技专项(2017ZF007) （2017ZF007）
中国医学科学院医学与健康科学创新工程(2017-12M-3-022) （2017-12M-3-022）
